Clinical Trials Browser

Adenocarcinoma × pembrolizumab × 90 days × Clear all

NCT06901531 2026-03-11

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06561685 2026-02-10

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Phase 2 Not yet recruiting

Adenocarcinoma, Uterine Cervical Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms